Cargando…

The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy

Lung cancer is the most common cancer worldwide. Disappointingly, despite great effort in encouraging screening or, at least, a close surveillance of high-risk individuals, most of lung cancers are diagnosed when already surgically unresectable because of local advancement or metastasis. In these ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Visconti, Roberta, Morra, Francesco, Guggino, Gianluca, Celetti, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5535867/
https://www.ncbi.nlm.nih.gov/pubmed/28653990
http://dx.doi.org/10.3390/ijms18071374
_version_ 1783253912435818496
author Visconti, Roberta
Morra, Francesco
Guggino, Gianluca
Celetti, Angela
author_facet Visconti, Roberta
Morra, Francesco
Guggino, Gianluca
Celetti, Angela
author_sort Visconti, Roberta
collection PubMed
description Lung cancer is the most common cancer worldwide. Disappointingly, despite great effort in encouraging screening or, at least, a close surveillance of high-risk individuals, most of lung cancers are diagnosed when already surgically unresectable because of local advancement or metastasis. In these cases, the treatment of choice is chemotherapy, alone or in combination with radiotherapy. Here, we will briefly review the most successful and recent advances in the identification of novel lung cancer genetic lesions and in the development of new drugs specifically targeting them. However, lung cancer is still the leading cause of cancer-related mortality also because, despite impressive initial responses, the patients often develop resistance to novel target therapies after a few months of treatment. Thus, it is literally vital to continue the search for new therapeutic options. So, here, on the basis of our recent findings on the role of the tumor suppressor CCDC6 protein in lung tumorigenesis, we will also discuss novel therapeutic approaches we envision for lung cancer.
format Online
Article
Text
id pubmed-5535867
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-55358672017-08-04 The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy Visconti, Roberta Morra, Francesco Guggino, Gianluca Celetti, Angela Int J Mol Sci Commentary Lung cancer is the most common cancer worldwide. Disappointingly, despite great effort in encouraging screening or, at least, a close surveillance of high-risk individuals, most of lung cancers are diagnosed when already surgically unresectable because of local advancement or metastasis. In these cases, the treatment of choice is chemotherapy, alone or in combination with radiotherapy. Here, we will briefly review the most successful and recent advances in the identification of novel lung cancer genetic lesions and in the development of new drugs specifically targeting them. However, lung cancer is still the leading cause of cancer-related mortality also because, despite impressive initial responses, the patients often develop resistance to novel target therapies after a few months of treatment. Thus, it is literally vital to continue the search for new therapeutic options. So, here, on the basis of our recent findings on the role of the tumor suppressor CCDC6 protein in lung tumorigenesis, we will also discuss novel therapeutic approaches we envision for lung cancer. MDPI 2017-06-27 /pmc/articles/PMC5535867/ /pubmed/28653990 http://dx.doi.org/10.3390/ijms18071374 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Commentary
Visconti, Roberta
Morra, Francesco
Guggino, Gianluca
Celetti, Angela
The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy
title The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy
title_full The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy
title_fullStr The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy
title_full_unstemmed The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy
title_short The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy
title_sort between now and then of lung cancer chemotherapy and immunotherapy
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5535867/
https://www.ncbi.nlm.nih.gov/pubmed/28653990
http://dx.doi.org/10.3390/ijms18071374
work_keys_str_mv AT viscontiroberta thebetweennowandthenoflungcancerchemotherapyandimmunotherapy
AT morrafrancesco thebetweennowandthenoflungcancerchemotherapyandimmunotherapy
AT gugginogianluca thebetweennowandthenoflungcancerchemotherapyandimmunotherapy
AT celettiangela thebetweennowandthenoflungcancerchemotherapyandimmunotherapy
AT viscontiroberta betweennowandthenoflungcancerchemotherapyandimmunotherapy
AT morrafrancesco betweennowandthenoflungcancerchemotherapyandimmunotherapy
AT gugginogianluca betweennowandthenoflungcancerchemotherapyandimmunotherapy
AT celettiangela betweennowandthenoflungcancerchemotherapyandimmunotherapy